GUJTHEM.NS

Gujarat Themis Biosyn Limited

NSEHealthcare

₹389.40

▼ -1.67%-₹6.60 today

₹0.00₹0.00

Ask Warren

Open

₹0.00

Prev close

₹396.00

Day range

₹0 – ₹0

52W range

₹225.05 – ₹479

Volume

1.2L

Avg vol (20D)

1.6L

Mkt cap

₹4,205.51Cr

P/E TTM

90.2×

Trade Gujarat Themis Biosyn Limited with Artha

Company Metrics

Revenue (ttm)₹165.82 Cr

Net Income (ttm)₹0.00

Shares Out10.90 Cr

EPS (ttm)

Forward PE

Dividend

Ex-Dividend DateInvalid Date

Trading Metrics

Beta0.34

About GUJTHEM.NS

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India and Japan. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.

IndustryDrug Manufacturers - Specialty & Generic

SectorHealthcare

Employees0

Stock ExchangeNSE

Ticker SymbolGUJTHEM.NS

Websitehttps://www.gtbl.in

GUJTHEM.NS · NSE

Financial Performance

In 2026, Gujarat Themis Biosyn Limited's revenue was ₹165.82 Cr, an increase of +17.20% compared to the previous year. Earnings were ₹0.00, an decrease of +9.10%.

Revenue (2026)

₹165.82 Cr

↗+17.20% YoY

Earnings (2026)

₹0.00

↘-9.10% YoY

Year-over-Year Growth

Revenue

+17.20%

Earnings

-9.10%

News

Save watchlists across devicesSet price alerts that buzz your phoneConnect Zerodha for one-tap trades

Create free account